Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AL-335 in Healthy Volunteers and Hepatitis C Patients
NCT02339207Phase 1Completed
- Sponsor
- Alios BioPharma
- Start
- Dec 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in hepatitis C (HCV) comparing Placebo with Adafosbuvir (2 arms). Primary endpoint: Number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG and abnormal clinical laboratory results at Day 21. Started Dec 2014; status: completed.
02
Drugs
adafosbuvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02339207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02339207.